Gordon, Aaron
Geschwind, Daniel H.
Funding for this research was provided by:
Autism Science Foundation (18-004)
Brain and Behavior Research Foundation (27358)
National Institute of Mental Health (5U01 MH115746)
California Institute of Regenerative Medicine (GC1R-06673)
Article History
Received: 23 December 2019
Accepted: 1 April 2020
First Online: 16 April 2020
Ethics approval and consent to participate
: Not applicable
: Not applicable
: DHG serves as a scientific advisor for Ovid Therapeutics, which is developing therapeutics for rare neurodevelopmental disorders.